The total study sample comprised 1,076 APOE ε4 carriers (17.5%) and 5,084 APOE ε4 noncarriers (82.5%) with an average age of 90.1 ± 7.2 years, and among them, 1,267 (24.9%) had cognitive impairment. Here, APOE is linked to Cognitive impairment.